Swiss Helvetia Fund is a non-diversified, closed-end investment company whose objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The Fund also may acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.
| Company | Date | Round | Size | Participants |
| Synosia Therapeutics | 10/10 | Series C | $30M | 7 |
| Synosia Therapeutics | 1/09 | Series B | $29M | 7 |
